Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
QS-21 is a highly purified triterpene saponin derived from the bark of the Quillaja saponaria tree, widely recognized as a potent vaccine adjuvant that enhances both humoral and cellular immunity [1, 12]. It modulates a diverse array of immune cells, primarily targeting antigen-presenting cells (APCs) such as dendritic cells and macrophages, as well as T cells and natural killer (NK) cells [1, 4]. The primary molecular mechanism of QS-21 involves the activation of the NLRP3 inflammasome in APCs, which triggers the secretion of pro-inflammatory cytokines like IL-1β and IL-18, driving a Th1-biased immune response [2, 6]. Additionally, QS-21 facilitates the cross-presentation of exogenous antigens to CD8+ T cells by inducing lysosomal membrane destabilization, allowing antigens to escape into the cytoplasm and enter the MHC class I pathway [4, 7]. It may also provide direct co-stimulatory signals to T cells through its aldehyde group, which can form Schiff bases with cell surface receptors like CD2 [1, 13]. Due to its inherent toxicity (e.g., hemolysis) and reactogenicity, QS-21 is typically formulated in lipid-based adjuvant systems like AS01 or Matrix-M to improve safety and stability [9, 12]. These systems are critical components of several licensed vaccines, including those for shingles (Shingrix), malaria (Mosquirix), and respiratory syncytial virus (Arexvy) [11, 12].
QS-21 modulates immune cells by facilitating antigen cross-presentation through lysosomal destabilization and escape into the cytosol, activating the NLRP3 inflammasome in antigen-presenting cells (APCs) to release IL-1β and IL-18, and potentially providing co-stimulatory signals to T cells via its aldehyde group [1, 2, 4].
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Immune cells (QS-21 modulated).